Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nyxoah SA, a medical technology firm based in Mont-Saint-Guibert, Belgium, has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 15, 2026, in San Francisco. The presentation will commence at 12:00 PM PT, showcasing Nyxoah’s innovations in treating Obstructive Sleep Apnea (OSA) through neuromodulation. Investors can access a live audio webcast of the event via the company's investor relations page.

focused on combating the prevalent health issue of OSA, Nyxoah has developed the Genio system, a patient-friendly, leadless, and battery-free hypoglossal neurostimulation therapy. OSA, recognized as the most common sleep-related breathing disorder, poses significant risks, including increased mortality and cardiovascular diseases. Nyxoah's mission is to empower OSA patients to achieve restorative sleep and improve their overall quality of life.

The Genio system received European CE Mark approval in 2019 following the successful BLAST OSA study, marking a significant milestone for the company. Additionally, Nyxoah has conducted two successful Initial Public Offerings (IPOs) on Euronext Brussels in September 2020 and NASDAQ in July 2021. Recently, the company obtained CE mark approval to expand its therapeutic indications to patients with Complete Concentric Collapse (CCC), a condition not addressed by competitors' therapies.

Recently, Nyxoah announced favorable results from the DREAM IDE pivotal study, leading to FDA approval in August 2025 for a subset of adult patients with moderate to severe OSA. This signifies the company's expanding footprint in the medical technology industry, solidifying Nyxoah’s position as a leader in innovative OSA treatment solutions. For additional information, interested parties are encouraged to visit Nyxoah's official website.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) is poised to garner significant attention at the upcoming 44th Annual J.P. Morgan Healthcare Conference, a key event for healthcare investors and stakeholders. The presentation scheduled for January 15, 2026, will provide insights into its innovative Genio system, which leverages neuromodulation technology for the treatment of Obstructive Sleep Apnea (OSA).

The market for OSA treatments is expanding rapidly, driven by increasing awareness of the condition's health implications, including heightened mortality risks and cardiovascular issues. Nyxoah's Genio system, which is leadless and battery-free, distinguishes itself in a competitive landscape where many therapies involve invasive procedures and complications. This focus on patient-centered solutions could make Nyxoah an attractive prospect for investors looking to tap into the growing demand for effective, non-invasive OSA treatments.

Following successful clinical trials, including the BLAST OSA and BETTER SLEEP studies, Nyxoah has secured both European CE mark approval and FDA authorization, further enhancing its market credibility. The FDA approval for certain adult patients, especially for those with moderate to severe OSA, opens new revenue streams while solidifying Nyxoah's position in the U.S. market, which represents a significant opportunity given the higher acceptance and reimbursement landscape.

Investors should closely monitor Nyxoah's presentation at the conference for insights into commercial strategies and potential partnerships, as these could impact the stock's valuation. With a focus on expanding treatment indications, particularly for Complete Concentric Collapse (CCC) patients that competitors may overlook, Nyxoah’s strategic initiatives could position the company for substantial growth in the coming years.

In summary, Nyxoah presents a promising investment opportunity within a burgeoning sector. Stakeholders should consider the potential impact of upcoming developments post-conference, especially regarding market penetration and patient access, which could drive stock performance ahead.